Mood-stabilizing drugs: Mechanisms of action

Robert J. Schloesser, Keri Martinowich, Husseini K. Manji

Research output: Contribution to journalReview article

Abstract

Mood-stabilizing drugs are the most widely prescribed pharmacological treatments for bipolar disorder, a disease characterized by recurrent episodes of mania and depression. Despite extensive clinical utilization, significant questions concerning their mechanisms of action remain. In recent years, a diverse set of molecular and cellular targets of these drugs has been identified. Based on these findings, downstream effects on neural and synaptic plasticity within key circuits have been proposed. Here, we discuss recent data, identify current challenges impeding progress and define areas for future investigation. Further understanding of the primary targets and downstream levels of convergence of mood-stabilizing drugs will guide development of novel therapeutic strategies and help translate discoveries into more effective treatments with less burdensome adverse-effect profiles.

Original languageEnglish (US)
Pages (from-to)36-46
Number of pages11
JournalTrends in Neurosciences
Volume35
Issue number1
DOIs
StatePublished - Jan 2012
Externally publishedYes

Fingerprint

Neuronal Plasticity
Bipolar Disorder
Pharmaceutical Preparations
Pharmacology
Depression
Therapeutics

Keywords

  • Bipolar disorder
  • Lithium
  • Mania
  • Mood-stabilizing drugs
  • Neurotrophic factors
  • Synaptic plasticity

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Mood-stabilizing drugs : Mechanisms of action. / Schloesser, Robert J.; Martinowich, Keri; Manji, Husseini K.

In: Trends in Neurosciences, Vol. 35, No. 1, 01.2012, p. 36-46.

Research output: Contribution to journalReview article

Schloesser, Robert J. ; Martinowich, Keri ; Manji, Husseini K. / Mood-stabilizing drugs : Mechanisms of action. In: Trends in Neurosciences. 2012 ; Vol. 35, No. 1. pp. 36-46.
@article{b1aaef7c06ac43499c5ca53a5589e10b,
title = "Mood-stabilizing drugs: Mechanisms of action",
abstract = "Mood-stabilizing drugs are the most widely prescribed pharmacological treatments for bipolar disorder, a disease characterized by recurrent episodes of mania and depression. Despite extensive clinical utilization, significant questions concerning their mechanisms of action remain. In recent years, a diverse set of molecular and cellular targets of these drugs has been identified. Based on these findings, downstream effects on neural and synaptic plasticity within key circuits have been proposed. Here, we discuss recent data, identify current challenges impeding progress and define areas for future investigation. Further understanding of the primary targets and downstream levels of convergence of mood-stabilizing drugs will guide development of novel therapeutic strategies and help translate discoveries into more effective treatments with less burdensome adverse-effect profiles.",
keywords = "Bipolar disorder, Lithium, Mania, Mood-stabilizing drugs, Neurotrophic factors, Synaptic plasticity",
author = "Schloesser, {Robert J.} and Keri Martinowich and Manji, {Husseini K.}",
year = "2012",
month = "1",
doi = "10.1016/j.tins.2011.11.009",
language = "English (US)",
volume = "35",
pages = "36--46",
journal = "Trends in Neurosciences",
issn = "0378-5912",
publisher = "Elsevier Limited",
number = "1",

}

TY - JOUR

T1 - Mood-stabilizing drugs

T2 - Mechanisms of action

AU - Schloesser, Robert J.

AU - Martinowich, Keri

AU - Manji, Husseini K.

PY - 2012/1

Y1 - 2012/1

N2 - Mood-stabilizing drugs are the most widely prescribed pharmacological treatments for bipolar disorder, a disease characterized by recurrent episodes of mania and depression. Despite extensive clinical utilization, significant questions concerning their mechanisms of action remain. In recent years, a diverse set of molecular and cellular targets of these drugs has been identified. Based on these findings, downstream effects on neural and synaptic plasticity within key circuits have been proposed. Here, we discuss recent data, identify current challenges impeding progress and define areas for future investigation. Further understanding of the primary targets and downstream levels of convergence of mood-stabilizing drugs will guide development of novel therapeutic strategies and help translate discoveries into more effective treatments with less burdensome adverse-effect profiles.

AB - Mood-stabilizing drugs are the most widely prescribed pharmacological treatments for bipolar disorder, a disease characterized by recurrent episodes of mania and depression. Despite extensive clinical utilization, significant questions concerning their mechanisms of action remain. In recent years, a diverse set of molecular and cellular targets of these drugs has been identified. Based on these findings, downstream effects on neural and synaptic plasticity within key circuits have been proposed. Here, we discuss recent data, identify current challenges impeding progress and define areas for future investigation. Further understanding of the primary targets and downstream levels of convergence of mood-stabilizing drugs will guide development of novel therapeutic strategies and help translate discoveries into more effective treatments with less burdensome adverse-effect profiles.

KW - Bipolar disorder

KW - Lithium

KW - Mania

KW - Mood-stabilizing drugs

KW - Neurotrophic factors

KW - Synaptic plasticity

UR - http://www.scopus.com/inward/record.url?scp=84855337066&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855337066&partnerID=8YFLogxK

U2 - 10.1016/j.tins.2011.11.009

DO - 10.1016/j.tins.2011.11.009

M3 - Review article

C2 - 22217451

AN - SCOPUS:84855337066

VL - 35

SP - 36

EP - 46

JO - Trends in Neurosciences

JF - Trends in Neurosciences

SN - 0378-5912

IS - 1

ER -